Novo Nordisk is a world leader in diabetes treatment innovation and as such is committed to supporting novel research in protein-based therapies and technologies that have the potential to improve the effective treatment, prevention and/or cure of diabetes.

In keeping with this commitment, Novo Nordisk R&D has renewed its research award program to support new and established scientists in their exploration of novel hypotheses in the area of diabetes and obesity research. The aim of this research award program is to help scientists substantiate early innovation research efforts and clarify if their hypotheses could result in new treatment options for diabetes and obesity.

Only non-clinical research proposals from scientist at US and Canadian academic and medical research institutions are eligible for support.

The award program also targets novel research ideas that despite having potentially high impact would not normally attract funding from such institutions as the National Institutes of Health (NIH) or the Canadian Institutes of Health Research (CIHR).

Under the program, Novo Nordisk R&D offers two types of research funding opportunities: "Early Research Exploration" or "Proof of Principle" awards. The awards are reserved for nonclinical research only and projects can be supported for up to two years under the program.

More about Diabetes Innovation Award Program